Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/30/2025

Initiating Hydralazine in Heart Failure with Reduced Ejection Fraction

Introduction to Hydralazine Therapy

  • The European Society of Cardiology recommends hydralazine when hypertension persists despite treatment with an ACE inhibitor, beta-blocker, mineralocorticoid receptor antagonist, and diuretic in patients with heart failure with reduced ejection fraction (HFrEF) 1, 2
  • The American College of Cardiology recommends ensuring the patient is on maximally tolerated doses of ACE inhibitor, beta-blocker, and mineralocorticoid receptor antagonist before considering hydralazine 1, 3, 4

Stepwise Approach to Initiating Hydralazine

  • The European Society of Cardiology suggests verifying adequate diuretic therapy, with loop diuretics preferred over thiazides in patients with chronic kidney disease stage 3B or worse 1, 2, 4
  • Amlodipine is recommended as the preferred third-line agent for blood pressure control, with a Class I, Level A recommendation 1, 2
  • Felodipine is an alternative dihydropyridine calcium channel blocker, with a Class IIa, Level B recommendation 1, 2

Special Considerations for Hydralazine Use

  • The American College of Cardiology recommends hydralazine combined with isosorbide dinitrate for self-described African American patients with HFrEF and persistent symptoms, with a Class I, Level A recommendation 3, 7, 5, 6
  • The American Heart Association suggests referral to a heart failure specialist before using hydralazine in patients who cannot tolerate ACE inhibitors or ARBs 3, 7, 8, 9, 10

Contraindications and Precautions

  • The European Society of Cardiology advises against using moxonidine, due to increased mortality, with a Class III recommendation 1, 2, 5, 6
  • The American College of Cardiology recommends avoiding alpha-adrenergic blockers like doxazosin, as they can cause neurohumoral activation, fluid retention, and worsening heart failure, with a Class III recommendation 1, 2, 5, 6
  • The American Heart Association suggests never using non-dihydropyridine calcium channel blockers in HFrEF, with a Class III recommendation 1, 2, 5, 6

REFERENCES

4

Uncontrolled Hypertension Management in CKD Stage 3B [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025